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BRIEF REVIEW 
Recent Progress Toward Understanding the 
Molecular Biology of Von RecMrnghausen 
Neurofibromatosis 
David H. Gutmann, MD, PhD, and Francis S .  Collins, MD, PhD 
The gene for von Recklinghausen neurofibromatosis (NF 1) was recently identified by positional cloning and found to 
code for a large, ubiquitously expressed protein. This protein has both structural and functional similarity to a family 
of proteins with guanosine triphosphatase-activating properties, involved in the regulation of the protooncogene ras. 
One of the postulated functions of the NFI gene product may relate to its ability to regulate ras-mediated cell 
proliferation. Selective pharmacotherapy directed at downregulating ras may be of benefit to patients with NF1. 
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Neurofibromatosis type 1 (NFl), or von Reckling- 
hausen neurofibromatosis, is one of the most common 
autosomal dominant disorders in humans. It is char- 
acterized by abnormalities affecting tissues derived 
primarily, but not exclusively, from the neural crest, 
including multiple neurofibromas, cafe-au-lait spots, 
axillary freckling, Lisch nodules of the iris, distinct 
bony lesions, and optic nerve gliomas [l]. The NFI 
locus is unusual in that the spontaneous mutation rate 
is estimated to be 100-fold higher than the usual rate 
for a single locus; 30 to 50% of cases represent new 
mutations [ 11. The risk of malignancy is also increased, 
especially for neurofibrosarcomas and brain tumors 
c21. 
Early linkage analysis demonstrated that the locus 
for NF2 resides on chromosome 17 131. The identifi- 
cation of two patients with chromosome 17 transloca- 
tions facilitated the identification of the gene for NFI 
14-61. Further chromosomal and cDNA walking cul- 
minated in the determination of the entire NFl coding 
sequence C7f. 
The NFl Gene 
The gene for NFI spans approximately 300 kb of ge- 
nomic DNA and encodes an approximately 13-kb mes- 
senger RNA with an open reading frame of 8,454 nu- 
cleotides [7] (Fig 1). The predicted protein product is 
2,818 amino acids with a predicted molecular mass of 
327 kd 171. Forty-nine exons and two alternatively 
spliced mRNA isoforms have been identified. An un- 
expected finding was the discovery of three genes em- 
bedded within one intron of the NFI gene. These 
three genes, OMgp {S), EVI2A [9}, and EVI2B {lo], 
are transcribed in the opposite orientation as the NFI 
gene and their contribution to the disease is uncertain. 
In fact, the phenotype of disease in patients with dele- 
tions of OMgp, EVI2A, and EVI2B is the same as that 
of patients with point mutations in the NFI gene 
C4-61, indicating that the embedded genes may not 
affect the usual manifestations of the disease. Two of 
these genes, EVI2A and EVI2B, are human homo- 
logues of putative mouse protooncogenes that may 
play a role.in the pathogenesis of murine myeloid tu- 
mors. Juvenile chronic myelogenous leukemias have 
keen reported to occur more frequently in NF1 pa- 
tients than in the general population, suggesting a pos- 
sible role for these genes in NF1-related myeloid ma- 
lignancies {2]. However, thus far, there is no evidence 
for mutations in these genes in NF1 patients or signifi- 
cant differences in the abundance of EVI2A and 
EVI2B mRNA in NF1 patients. Of additional interest 
is the OMgp gene, encoding an abundant myelin pro- 
tein (oligodendrocyte-myelin glycoprotein), which 
was previously thought to be a good candidate for the 
NFI gene, given its role in central nervous system 
cell-cell communication El 11. Again, there is no evi- 
dence to directly implicate the OMgp gene in the 
pathogenesis of NFI. 
The mRNA for NFI is ubiquitously expressed, sug- 
gesting that the neural crest predominance of abnor- 
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Fig  I .  Schematic representation of the NF1 gene. (A) The geno- 
mii nmp ofthe NF1 locus depicts the two Not I restriction en- 
zyme recognition sites separated by approximate4 300 kb of  
DNA. The relationship between the initiation codon (ATG) ,  
the terniination codon ITGA). and the Not 1 sites is iIIus- 
trured. The peiitions of the translocation breakpoints from two 
NFI patients It{ I ;17) and t{l7;22}), which facilitated the 
identification of the NFI gene. are included. The embedded 
genej. OM@ 101, EV12B (2B1, and EVI2A (2A1, are shown 
aA being transcribed from the opposite D N A  strand as the NF1 
gene. ( B I  The neurofibromin protein is depicted with the GAP- 
reIated domain IGRD) and the six potential serinelthreonine 
phosphorylution sites (*). 
malities in NF1 is not the result of tissue-specific ex- 
pression of NFI mRNA 14, 7). Homologues of the 
N F l  gene have been identified in all vertebrate animals 
examined [12]. Analysis of the predicted amino acid 
sequence suggests that the N F l  gene product is a cyto- 
plasmic protein without a transmembrane-spanning re- 
gion. In addition, six potential serine/threonine phos- 
phorylation sites and a single tyrosine phosphorylation 
site, important in signal transduction molecules, have 
been identified (see Fig 1). 
Sequence analysis of the full-length cDNA reveals 
sequence similarity between a small portion of the 
NFI gene (NF I -guanosine triphosphatase [GTPaseI- 
activating protein {GAP)-related domain [NFlGRD}) 
and a family of GAPS in mammals and yeast (IRA1, 
IRA2) (131. The entire N F l  protein was originally 
termed NFI GAP-related protein (NFlGRP) to un- 
derscore the relationship between the NFlGRD, 
mammalian GAP 1147, and the yeast IRA1 and IRA2 
genes 1151. The consensus name for the NFI gene 
product is now neurofibromin. These GAP proteins 
accelerate the hydrolysis of ras-guanosine triphos- 
phate (GTP) to ras-guanosine diphosphate (GDP), 
converting the protooncogene protein, m s ,  from the 
active to the inactive form E16). Although the precise 
role of ras in mammalian cells is not clear, it appears 
to play significant roles in growth factor-mediated pro- 
liferation and neoplasia (see Function of neurofibromin 
section below). The ability of the N F l G R D  to function 
as a GAP-related protein in vivo and in vitro was dem- 
onstrated independently by three groups 11 7-19}. 
The NFI Protein 
The protein product of the NFI locus has recently 
been identified (120, 21), Basu TN,  Gutmann D H ,  
Fig 2 .  lmmunoprecipitation of neurofibromin using two difler- 
ent rabbit antisera ( F F I  , B3Ai directed against distinct regions 
of  the protein. The relationship of these antisera epitopes to the 
f N l I  length nearofbromin molecule is illustrated. T h e  antisera 
were generated as previous(y described 1{20}, Gutmann DH,  
unpublished results). Human HeLU cells radiolabeled witb "S- 
methionine overnight were Lyzed and immunoprecipitated before 
separation by 7.5 @ sodium dodecy l su(fate-po(yacvylamide gel 
electrophoresis and autoradiography for 3 days. The positions o j  
the molecular weight markexr in kd are shouin at the Ie) mar- 
gin. Neurofbromin migrates as a 250-kd protein (arrow) 
Collins FS, and Downward J, unpublished data). 1Jsing 
antibodies generated against fusion proteins and syn- 
thetic peptides, a unique 250-kd protein was found in 
all tissues and cell lines examined ([207; Fig 2). Immu-. 
noblot analysis of adult mouse tissues demonstrated 
the highest levels of expression in brain, kidney, and 
spleen 120). The difference between the predicted1 mo- 
lecular mass (327 kd) and the observed size (250 kd) 
is most likely due to anomalous migration and not 
to protein processing (Gutmann DH, unpublishe'd re- 
sults). This protein was localized to the cytoplasm by 
two different methods, differential centrifugation 
(Basu TN, Gutmann D H ,  Collins FS, and Downward 
J, unpublished data) and glycerol gradients [2 11. Indi-. 
rect immunoff uorescence using antibodies generated 
against neurofibromin likewise demonstrated cyto- 
plasmic localization (Gregory PE, Gutmann DH, Bo- 
guski M, Wood DL, and Collins FS, unpublished data). 
Neurofibromin appears to colocalize with microtu- 
bules in all cell types examined by imrnunofluores- 
cence and biochemical purification, suggesting that 
neurofibromin is intimately associated with cytoskele- 
tal elements (Fig 3). 
Function of Neurofibromin 
Undifferentiated cells contain the genetic capacity for 
rapid growth during embryonic development as .well 
as differentiation into specific tissues. In addition to 
genes that facilitate growth and differentiation (proto- 
oncogenes), cells also contain genes that code for pro- 
teins that inhibit these processes. The genes that down- 
regulate the expression of growth-promoting factors 
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Fig  3. ImmunofEuorescence of  fibroblast cells demonstrating the 
colocalization of neurof bromin and microtubules. Kangaroo rat 
fibroblast ( P l N  cells uiere incubated with rhodamine-labeled 
anti-p-tubulin (A) und fEuorescein-labeled anti-neurofibromin 
lB3A) antiserum (B) .  The Ptubulin monoclonal antibody 
stains microtubules. 
are termed tumor suppressor genes 1221. Progression 
to malignancy, or transformation, can therefore arise 
as a result of activating mutations in genes that facilitate 
cell growth (e.g., protooncogenes) or inactivating mu- 
tations in genes that inhibit these processes (tumor sup- 
pressor genes). Evidence for the existence of these tu- 
mor suppressor genes is based in part on the genetic 
predisposition of certain individuals to some pediatric 
malignancies; fusion of normal cells with certain pediat- 
ric tumor cells leads to suppression of the tumorigenic 
phenotype and chromosomal loss often accompanies 
the return to the neoplastic state. Tumor formation or 
transformation occurs when these genes are inacti- 
Tumor Suppressor Genes 
vated, implying that their normal function is to limit 
cell proliferation. This mechanism, originally known as 
the Knudson hypothesis, has been most thoroughly 
demonstrated for the retinoblastoma gene 1231. The 
known tumor suppressor genes are listed in the Table. 
In an inherited cancer syndrome, like NF1, each 
somatic cell in an affected individual has one normal 
copy of the NFI gene; the other copy is inherited as 
a mutant gene. However, in the abnormal neural crest 
tissues, the one remaining normal NFI gene is hypoth- 
esized to undergo somatic mutation to render both 
copies nonfunctional (C231; Fig 4). The loss of both 
normal NFl genes in neurofibromas has not yet been 
formally demonstrated. However, recent evidence has 
shown that both NFI genes are indeed disrupted in 
some neurofibrosarcoma cell lines (Legius E, unpub- 
lished results). 
It is appealing to postulate that neurofibromin acts 
as a tumor suppressor by regulating some intracellular 
protein essential for cell growth and proliferation (Fig 
5) .  One such protein, rus, has been shown to be impor- 
tant in growth factor-mediated cell proliferation. 
Overexpression of r u ~  in fibroblasts leads to transfor- 
mation, whereas anti-ras antibody injection blocks 
these events 124, 251. It has been established that a 
small portion of neurofibromin expressed alone 
(NFlGRD) can inactivate rus by accelerating ras GTP 
hydrolysis 117-191. If the major function of neurofi- 
bromin in cells is to downregulate ras, then loss of 
neurofibromin through mutation would lead to cell 
proliferation and transformation. Examination of some 
neurofibrosarcoma cell lines has demonstrated elevated 
Tumor Chromosomal Proposed 
Suppressor Gene Location Site of Action Mechanism Human Tumors 
Retinoblastoma 
Wilms’ tumor 
Mutated in colon 
cancer (MCC) 
Deleted in colon 
cancer (DCC) 
Adenomatous 
polyposis coli (APC) 
P53 




1 7 ~ 1 3  





Nucleus Transcription factor Nephroblastoma, 
hepatoblastorna 
2 ) Colon cancer 
? Cell ? Cellular adhesion Colon cancer 
Cytoplasm > Colon cancer 
membrane molecule 





Cytoplasm Interaction Neurohbrosarcoma, Neurofibromatosis 17q11.2 
with p2 1 -ras neurofibroma type 1 
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F i g  4. Illir~tratiori of the Knudson hypothesij as applied to neu- 
rofbromuto.ris type I (NFI i .  I n  u typical Schumn cell from u 
patient u’ith N F I ,  one copy ofthe two NF1 genes has been in- 
herited us a nonfitrictionul ropy (striped area of chromosomei. I t  
is po,ctuluted that somatic mutation o f  the one remaining fine- 
tionul NF1 gene in that Schusann re/! results in 1o.r.r of NF1- 
mediuted suppres.iion o f  prolif ration, 1-ulminating in neoplasiu 
snd the formaiion of nrurofbromas und neuro/ibrosurcomas. 
ras-GTP levels and reduced neurofibromin expression, 
perhaps as a result of mutations in the NFI gene in 
these cells [26]. 
In normal cells the role of neurofibromin has not 
been established. GAP, the mammalian GTPase m i -  
vating protein, is phosphorylated on tyrosine residues 
in response to growth factor stimulation and becomes 
associated with other signal transduction proteins 127). 
This tyrosine phosphorylation event inactivates GAP, 
resulting in increased ras-GTP levels [28 J. Neurofi- 
bromin, on the other hand, is phosphorylated on serine 
and threonine residues in response to growth factor 
stimulation and may become inactivated in an analo- 
gous manner to GAP (Basu TN, Gutmann DH, Col- 
lins FS, and Downward J, unpublished data). Based on 
the similarity to GAP, neurofibromin can be postulated 
to downregulate ras in the absence of growth factor 
stimulation but is inactivated in response to growth 
factors as part of a signal transduction pathway leading 
to ras activation and cell proliferation (see Fig 5 ) .  
The apparent ubiquitous expression of the NFI pro- 
tein represents a contrast to the predominance of  neu- 
ral crest involvement in this disease. Recent evidence 
suggests that neurofibromin is expressed predomi- 
nantly in brain, kidney, and spleen with detectable lev- 
els in white blood cells (D. H. Gutmann, unpublished 
data). Immunohistochemical analysis of adult tissues 
demonstrates expression of neurofibromin in central 
nervous system neurons, Schwann cells, dorsal root 
ganglia and adrenal medulla (FS Collins laboratory. 
unpublished results). Possibly, the  tissue specificity ot 
this disease may reflect an association between the N F I  
protein and other cellular signal transduction mole- 
cules that are expressed predominantly in tissues de- 
rived from neural crest. 
Mutations in Patients with N F l  
Examination of patients with NF1 by DNA, RNA, 
and protein analysis is still in its infancy. To date, the 
following two types of mutations have been described 
in NF1 patients: (1) large megabase deletions in pa- 
tients with NF1 and mental retardation and (2)  smaller 
kilobase deletions, translocations, and microalterations. 
Large deletions involving huge stretches of DNA in- 
cluding the entire NFI locus have been described in 
patients with “classic” NF1 and significant mental retar- 
dation C291. These deletions probably eliminate other 
genes involved in central nervous system development 
in addition to the NFI gene to account for the mental 
retardation. Smaller deletions and translocations inter- 
rupting the NFI gene have been reported (f4,  61, Wal- 
lace M, unpublished results; Legius E, unpublished re- 
sults). One patient with a single nucleotide mutation 
creating a stop codon and presumably an abnormal pro- 
tein has been described 161. Preliminary studies exam- 
ining fibroblast and white blood cell lines from NF1 
patients have thus far failed to detect abnormally mi- 
grating neurofibromin proteins (Gutmann DH, unpub- 
lished data), as was reported for dystrophin in Du- 
chenne and Becker muscular dystrophy patients [ 3 0 ] .  
At this time, there is no clear correlation between the 
site of the NFI mutation and the clinical phenotype; 
in fact, there is not expected to be much phenotype- 
genotype correlation because of the great variability in 
phenotype within NF1 families. 
Future Directions 
The Role of NF1 as a Tumor Supprrs8or Gme 
There is still much to learn about neurohbromin anti 
its role in tumor biology, cell growth, and develop- 
ment. One function of a small portion of neurofi- 
bromin (10% of the entire molecule) has been deline- 
ated, but it remains to be proved that the entire 
neurofibromin molecule can downregulate rat. What 
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Fig  5 .  One possible mechanism for neurofibromin-mediated cell 
prolifrration suppresJion. (A) In the resting state, neurofibromin 
(NFIGRP) is in  the active, dephosphorylated form and acceler- 
ates the conversion of p2 l  -ras from the active guanosine triphos- 
phate (GTP)-bound to  the inactice guanosine diphosphate 
iGDP)-bound form (thick line). When the majority of ras is in  
the inactiw form. there is little o r  no m%ulation of downstream 
cell proliferation puthunays. (BJ In the growth factor (GFI- 
stimulated state, binding of the GF ligand to  its appropriate re- 
ceptor IGFR) results in serinelthreonine phospho rylation of neu- 
rojibromin INFl GRP).  converting neurofibromin t o  its inactive 
form. When neuroflbromin is in the inactive form. ras remains 
in the active GTP-bound state and stimulates downstream 
pathu1ay.r culminating in  cell prolifevation. Likewise, inactiva- 
tion of neurofbromin by mutation in neural crest-derived tis- 
sues might result in  a predominance of the active GTP-bound 
ras and cell proliferation. 
does the rest of neurofibromin do? Preliminary results 
suggest that neurofibromin immunoprecipitated from 
cells indeed has GTPase accelerating activity (Down- 
ward J, Gutmann D H ,  unpublished data), but there is 
no proof that this is its only function within cells. The 
association of neurofibromin with cytoskeletal struc- 
tures, such as microtubules, suggests perhaps another 
function for the NFl protein. Microtubule assembly 
and disassembly is a GTP-dependent process; microtu- 
bules assemble and elongate when the tubulin mono- 
mer building blocks are in the GTP form and dissociate 
when the polymerized tubulin subunits are in the G D P  
form. Control of the GTP state of tubulin could be 
analogous to the control of yas guanosine phosphoryla- 
tion because it requires both GTPase-activating pro- 
teins and guanine nucleotide-replacing proteins [ 3  11. 
Dynamin, a microtubule-associated protein, was re- 
cently cloned and shown to have intrinsic GTPase ac- 
tivity [321. Analysis of the predicted amino acid se- 
quence revealed a guanosine nucleotide-binding 
domain distantly related to ras and other similar pro- 
teins. Dynamin appears to be involved in the bundling 
and tight association of microtubule filaments as well 
as in the transport of vesicles during endocytosis 133, 
341. One could postulate that neurofibromin acts as a 
GAP to direct cytoarchitectural changes in the cell in 
response to growth factors. If neurofibromin is analo- 
gous to GAP, in that phosphorylation downregulates 
its activity [28), then inhibition of neurofibromin's role 
in limiting cell proliferation through either ru.r and/or 
some interaction with microtubule elements could be 
envisioned to result in unlimited cell growth or trans- 
formation. 
NFl Animal Models 
Much effort is being invested in several laboratories to 
create a mouse model for NF1 by creating a germline 
knockout of the NFl gene, and the resulting pheno- 
type will be of considerable interest. Previously, 
transgenic mice generated by introducing the human 
T-lymphotropic virus type 1 (HTLV-I) tat gene into 
the germline produced animals with tumors morpho- 
logically similar to neurofibromas [35}. However, the 
link between HTLV-I infection and NF1 remains to 
be established. Multiple peripheral neurofibromas 
were produced in hamsters after transplacental intro- 
duction of N-nitroso-N-ethylurea, but these animals 
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References also developed Wilms' tumors, a tumor type not seen 
in NF1 patients [36]. 
D N A  Diagnosi.: in N F l  
Now that the entire NFl  gene has been cloned and 
sequenced, it is possible to study gene mutations in 
patients with NF1. The approaches taken to screen 
patients with NF1 for mutations will necessitate a com- 
bined approach of DNA, RNA,  and protein analysis. 
Given the high rate of spontaneous mutation in NF1 
and the large size of the gene, the search for causative 
mutations may be quite laborious. In fact, clinical appli- 
cation of DNA analysis in the diagnosis of NF1 is still 
not a reality. It is possible that mutations in different 
regions of the NFl gene will produce different pheno- 
types, as has been demonstrated for mutations within 
the dystrophin gene. As was true with the dystrophin 
gene where other related but distinct disorders may be 
caused by mutations within the same gene, it is impor- 
tant to study neurological disorders with abnormalities 
similar to those found in patients with NF1 for alter- 
ations in the NFI gene. The ideal proof that any given 
DNA or  protein mutation actually results in the dis- 
ease will require demonstration that replacement of 
the wild type but not mutant NFI in NFZ-deficient 
cells corrects the abnormal phenotype. To date, no 
such assay is available. 
lbhrrupy 
The cloning of the NFI gene opens the door to a more 
complete understanding of N F  1 pathobiology with the 
goal of designing specific, nonsurgical treatments for 
affected patients. The finding of elevated m.$-GTP lev- 
els in tumors from NF1 patients suggests that the in- 
ability of neurofibromin to downregulate may have 
something to do with the development of neurofi- 
bromas. Ru.1 is normally found in the cytoplasm but 
becomes membrane associated after the addition of a 
farnesyl lipid group tfarnesylation). Oncc associated 
with the membrane, ya.i participates in events that cul- 
minate in transformation. Drugs that inhibit farnesyla- 
tion have been shown to inhibit the mitogenic effects 
of growth factors and the tumorigenic properties of 
neuroblastoma cells (reviewed in 137)j. More useful 
therapies might involve drugs thar inhibit farnesyl 
transferase (addition of farnesyl group to the m.r pro- 
tein,, rather than lovastatin and cornpactin, which block 
farnesyl synthesis. Further study of these and related 
drugs may provide useful therapies for NFI patients. 
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